Flexion Therapeutics, Inc. (NASDAQ:FLXN) insider Yamo Deniz purchased 1,000 shares of the stock in a transaction dated Tuesday, September 5th. The shares were acquired at an average cost of $24.20 per share, for a total transaction of $24,200.00. Following the completion of the acquisition, the insider now owns 5,000 shares of the company’s stock, valued at $121,000. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Yamo Deniz also recently made the following trade(s):

  • On Friday, September 1st, Yamo Deniz purchased 3,000 shares of Flexion Therapeutics stock. The shares were acquired at an average cost of $24.15 per share, for a total transaction of $72,450.00.
  • On Thursday, August 31st, Yamo Deniz purchased 1,375 shares of Flexion Therapeutics stock. The shares were acquired at an average cost of $25.40 per share, for a total transaction of $34,925.00.

Flexion Therapeutics, Inc. (NASDAQ FLXN) opened at 24.12 on Monday. Flexion Therapeutics, Inc. has a 12-month low of $15.88 and a 12-month high of $29.41. The company’s market cap is $769.55 million. The firm has a 50-day moving average price of $23.25 and a 200-day moving average price of $22.01.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.11). On average, analysts forecast that Flexion Therapeutics, Inc. will post ($3.70) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Flexion Therapeutics, Inc. (FLXN) Insider Acquires $24,200.00 in Stock” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/09/18/flexion-therapeutics-inc-flxn-insider-acquires-24200-00-in-stock.html.

FLXN has been the topic of a number of research analyst reports. BMO Capital Markets reaffirmed a “buy” rating on shares of Flexion Therapeutics in a report on Friday, August 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price target (up from $34.00) on shares of Flexion Therapeutics in a report on Thursday, August 10th. Cantor Fitzgerald set a $40.00 price target on Flexion Therapeutics and gave the company a “buy” rating in a report on Monday, June 12th. Janney Montgomery Scott reaffirmed a “buy” rating and set a $35.00 price target (up from $30.00) on shares of Flexion Therapeutics in a report on Wednesday, July 12th. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and set a $44.00 price target on shares of Flexion Therapeutics in a report on Friday, July 7th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $31.50.

A number of institutional investors and hedge funds have recently modified their holdings of FLXN. Fiduciary Trust Co. acquired a new position in shares of Flexion Therapeutics in the 2nd quarter valued at about $101,000. IFP Advisors Inc lifted its holdings in shares of Flexion Therapeutics by 24.5% in the 2nd quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 1,000 shares during the period. Advisor Group Inc. lifted its holdings in shares of Flexion Therapeutics by 205.9% in the 2nd quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after buying an additional 3,500 shares during the period. Voya Investment Management LLC lifted its holdings in shares of Flexion Therapeutics by 25.8% in the 2nd quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock valued at $261,000 after buying an additional 2,651 shares during the period. Finally, BB&T Securities LLC acquired a new position in shares of Flexion Therapeutics in the 2nd quarter valued at about $289,000. 82.75% of the stock is owned by institutional investors.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.